PMID- 37771164
OWN - NLM
STAT- MEDLINE
DCOM- 20231123
LR  - 20231123
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 16
IP  - 11
DP  - 2023 Jul-Dec
TI  - The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug 
      conjugate, in the treatment of advanced or recurrent ovarian cancer: a 
      meta-analysis.
PG  - 1141-1152
LID - 10.1080/17512433.2023.2262673 [doi]
AB  - INTRODUCTION: This meta-analysis aims to systematically analyze the efficacy and 
      toxicity of mirvetuximab soravtansine (MIRV) as second-line and above treatment 
      for advanced or recurrent ovarian cancer. METHODS: Candidate studies were 
      identified in PubMed, Embase, Cochrane Library, CNKI, and Wanfang databases up to 
      1 May 2023. Objective response rate (ORR), progression-free survival (PFS), the 
      incidence of adverse events (AEs), and incidence of grade >/= 3 AEs were extracted 
      and calculated by meta-analysis of merging ratios or mean to describe the 
      efficacy and toxicity of MIRV. RESULTS: Seven eligible prospective studies were 
      included in this meta-analysis, including 605 patients with advanced ovarian 
      cancer who received second-line or higher therapy. ORR of MIRV was 34.2% (95% 
      confidence interval [CI] 25.0-43.5), and PFS was 5.82 months (95%CI 4.47-7.18). 
      The overall incidence of AEs was 87.4% (95%CI 52.9-100.0) and the incidence of 
      grade >/= 3 AEs was 27.1% (95%CI 18.9-36.1). The most common AEs were vision 
      blurring, nausea, and diarrhea, with incidence of 46.7% (39.6-53.8), 41.8% 
      (34.0-49.9), and 41.3% (30.4-52.5), respectively. CONCLUSIONS: MIRV has definite 
      efficacy and good safety as a novel choice for second-line and above treatment of 
      advanced or recurrent FRalpha positive ovarian cancer. This may have promising 
      application in patients with platinum-resistant diseases. PROSPERO REGISTRATION 
      NUMBER: CRD42023428599.
FAU - Xu, Ke
AU  - Xu K
AUID- ORCID: 0000-0002-5520-5754
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China.
AD  - Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, Sichuan, China.
FAU - Wang, Tianlei
AU  - Wang T
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China.
FAU - Pan, Shenbin
AU  - Pan S
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China.
FAU - He, Jie
AU  - He J
AUID- ORCID: 0000-0003-4466-9251
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China.
AD  - Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital 
      of Chengdu Medical College, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20231122
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 98DE7VN88D (mirvetuximab soravtansine)
RN  - 0 (Immunoconjugates)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Ovarian Neoplasms/drug therapy
MH  - Prospective Studies
MH  - Drug Resistance, Neoplasm
MH  - Carcinoma, Ovarian Epithelial
MH  - *Immunoconjugates
OTO - NOTNLM
OT  - Adverse event
OT  - efficacy
OT  - folate receptor-alpha
OT  - mirvetuximab soravtansine
OT  - ovarian cancer
EDAT- 2023/09/29 06:43
MHDA- 2023/11/23 06:42
CRDT- 2023/09/29 02:14
PHST- 2023/11/23 06:42 [medline]
PHST- 2023/09/29 06:43 [pubmed]
PHST- 2023/09/29 02:14 [entrez]
AID - 10.1080/17512433.2023.2262673 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(11):1141-1152. doi: 
      10.1080/17512433.2023.2262673. Epub 2023 Nov 22.